Observational studies: goldmines of information on rare diseases (Q42352177)

27 October 2017

0 references

Observational studies: goldmines of information on rare diseases (English)

1 reference

27 October 2017

1 reference

Robert S Benjamin

1

1 reference

PMC publication ID

5427529

27 October 2017

language of work or name

English

0 references

publication date

12 May 2017

1 reference

27 October 2017

1 reference

27 October 2017

15

1 reference

27 October 2017

1

1 reference

27 October 2017

100

1 reference

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

27 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Evidence-based medicine. A new approach to teaching the practice of medicine

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5427529

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28494808

12 December 2020

inferred from PubMed ID database lookup

One step forward, two steps back

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28494808

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/S12916-017-0868-7

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4e7qmqgp6zgzhcok3rhhqhsuse

30 July 2022

Dimensions Publication ID

1085402730

0 references

Fatcat ID

release_4e7qmqgp6zgzhcok3rhhqhsuse

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4e7qmqgp6zgzhcok3rhhqhsuse

30 July 2022

https://api.fatcat.wiki/v0/release/4e7qmqgp6zgzhcok3rhhqhsuse

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/4e7qmqgp6zgzhcok3rhhqhsuse

PubMed publication ID

1 reference

30 July 2022